Objective: To comprehensively assess changes in non-motor symptom domains and MDS-UPDRS non-motor experiences of daily living following continuous subcutaneous FLC/FCD initiation.
Background: Non-motor symptoms (NMS) significantly impair quality of life in advanced Parkinson’s disease (PD), yet response to device-aided therapies remains incompletely characterized.
Method: Twenty-eight advanced PD patients were under went inpatient FLC/FCD initiation. Non-motor outcomes were evaluated using Non-Motor Symptoms Scale (NMSS; n = 15 with paired data) and MDS-UPDRS Parts I+II (n = 11 with paired data) at baseline and 6-month follow-up. Domain-level changes were analyzed.
Results: Total NMS burden improved significantly (−30.4 ± 19.4 points, 49.2% reduction, p = 0.0007; continuers: −33.3 ± 19.2, 57.7% reduction, p = 0.0005). MDS-UPDRS non-motor sub scores (Parts I+II) decreased markedly (−22.7 ± 9.3 points, 50.1% reduction, p = 0.001). Domain-level analysis revealed significant improvements across multiple NMS domains: cognition (−4.1 points, p = 0.005), anxiety (−3.4, p = 0.0075), pain (−3.0, p = 0.005), depression (−2.9, p = 0.008), urinary symptoms (−2.7, p = 0.008), apathy (−2.7, p = 0.018), physical fatigue (−2.0, p = 0.004), and impulse control disorders (−1.7, p = 0.007). The largest MDS-UPDRS domain improvements occurred in pain (−2.3, p = 0.002), sleep (−1.8, p = 0.016), daytime sleepiness (−1.5, p = 0.008), freezing (−1.5, p = 0.008), turning in bed (−1.3, p = 0.004), and speech (−1.2, p = 0.002).
Conclusion: Continuous subcutaneous FLD/FCD yielded robust, broad-spectrum improvements in non-motor symptom burden, particularly in pain, cognition, anxiety, sleep disturbances, and activities of daily living. These findings support the comprehensive therapeutic benefit of continuous levodopa delivery beyond motor symptom control.
To cite this abstract in AMA style:
K. Waqar, M. Thomas, Y. Abdelmajid, E. Freitas, R. Cabrito, RH. Battah, A. Anjum, SH. Mittal. Impact of Continuous Subcutaneous Foslevodopa/Foscarbidopa (FLC/FCD) on Non-Motor Symptom Burden in Advanced Parkinson’s Disease: Domain-Level Analysis [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/impact-of-continuous-subcutaneous-foslevodopa-foscarbidopa-flc-fcd-on-non-motor-symptom-burden-in-advanced-parkinsons-disease-domain-level-analysis/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/impact-of-continuous-subcutaneous-foslevodopa-foscarbidopa-flc-fcd-on-non-motor-symptom-burden-in-advanced-parkinsons-disease-domain-level-analysis/